Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Main Article Content
Keywords
long term efficacy, TYK2, deucravacitinib, plaque psoriasis
Abstract
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib treatment was superior to placebo and apremilast in the POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) trials in moderate to severe plaque psoriasis. We evaluated long-term clinical outcomes in patients with ≈2 years (112 weeks) of continuous deucravacitinib exposure.
Methods: PSO-1 and PSO-2 patients were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At Week 52, patients were eligible to enroll in the POETYK long-term extension (LTE; NCT04036435) trial and receive deucravacitinib 6 mg once daily. Efficacy outcomes included ≥75%/≥90% reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline (sPGA 0/1). Efficacy was assessed using modified nonresponder imputation through the data cutoff date of October 1, 2021 (Week 112) in patients receiving continuous deucravacitinib treatment from Day 1 and in patients receiving continuous deucravacitinib treatment who achieved PASI 75 at Week 24. As-observed data and results by treatment failure rules imputation were also analyzed.
Results: A total of 513 patients received continuous deucravacitinib from Day 1 in PSO-1/PSO-2 until Week 112 in the LTE, including 336 patients who had achieved PASI 75 at Week 24. High clinical response rates achieved at Week 52 in PSO-1/PSO-2 (PASI 75, 73.0%; PASI 90, 46.3%; sPGA 0/1, 58.5%) were maintained at Week 112 in the LTE (PASI 75, 76.2%; PASI 90, 48.3%; sPGA 0/1, 58.4%) among patients receiving continuous deucravacitinib treatment from Day 1. High response rates were also maintained in Week 24 PASI 75 responders (Week 52: PASI 75, 90.3%: PASI 90, 62.1%: sPGA 0/1, 73.8%; Week 112: PASI 75, 89.2%; PASI 90, 61.1%; sPGA 0/1, 70.5%). Results were consistent regardless of data imputation methodology.
Conclusion: Deucravacitinib was associated with sustained efficacy through 2 years in patients who received continuous treatment from Day 1 and in patients who achieved PASI 75 at Week 24. High clinical response rates achieved at Week 52 were maintained at Week 112. These findings provide additional support for deucravacitinib as an efficacious long-term treatment for moderate to severe plaque psoriasis.
References
2. Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022.
3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023.
4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022.
5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022.
6. Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co.; November 2022.
7. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.
8. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.
9. Strober B, et al. J Am Acad Dermatol. 2023;88:41-50.
10. Warren RB, et al. Presented at the 30th EADV Congress; 29 September-2 October 2021.
11. Langley RGB, et al. J Drugs Dermatol. 2017;16:734-742.
12. Papp K, et al. Br J Dermatol. 2021;185:1135-1145.
13. Reich K, et al. Br J Dermatol. 2021;185:1146-1159.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.